<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02187120</url>
  </required_header>
  <id_info>
    <org_study_id>APP1044894</org_study_id>
    <secondary_id>U1111-1160-6738</secondary_id>
    <nct_id>NCT02187120</nct_id>
  </id_info>
  <brief_title>Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)</brief_title>
  <acronym>PATCH</acronym>
  <official_title>A Multi-centre Randomised, Double-blinded, Placebo-controlled Trial of Pre-hospital Treatment With Tranexamic Acid for Severely Injured Patients at Risk of Acute Traumatic Coagulopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Research Council, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Monash University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine whether giving severely injured adults a drug
      called tranexamic acid (TXA) as soon as possible after injury will improve their chances of
      survival and their level of recovery at six months.

      After severe injury, a person may have uncontrolled bleeding that places them at high risk of
      bleeding to death. Coagulation (the formation of blood clots) is an important process in the
      body that helps to control blood loss. Up to a quarter of people that are severely injured
      have a condition called acute traumatic coagulopathy. This condition affects coagulation and
      results in the break down of blood clots (fibrinolysis) that can lead to increased blood loss
      and an increased risk of dying.

      TXA is an anti-fibrinolytic drug that might help to reduce the effects of acute traumatic
      coagulopathy by preventing blood clots from breaking down and helping to control bleeding. In
      Australia, TXA is approved for use by the Therapeutic Goods Administration (TGA) to reduce
      blood loss or the need for blood transfusion in patients undergoing surgery (i.e. cardiac
      surgery, knee or hip arthroplasty). Recent evidence from a large clinical trial (CRASH-2)
      showed early treatment with TXA reduced the risk of death in severely injured patients,
      however the majority of patients involved in the study were injured in countries where
      prehospital care is limited and rapid access to lifesaving treatments is limited compared to
      that available in countries like Australia and New Zealand. It is unclear whether TXA will
      reduce the risk of death to the same degree when it is given alongside other lifesaving
      treatments that are available to patients soon after injury in these countries.

      The hypothesis is that TXA given early to injured patients who are at risk of acute traumatic
      coagulopathy and who are treated in countries with systems providing advanced trauma care
      reduces mortality and improves recovery at 6-months after injury.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with a favourable outcome (moderate disability or good recovery, GOSE scores 5-8) compared to those who have died (GOSE 1), or have severe disability (GOSE 2-4).</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Units of blood products used (red blood cells, plasma, platelets, prothrombin complex concentrate, fibrinogen, Factor VIIa, cryoprecipitate)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation assessed using the international normalised ratio (INR)</measure>
    <time_frame>Immediately upon patient arrival to hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation assessed using the international normalised ratio (INR)</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation assessed using the international normalised ratio (INR)</measure>
    <time_frame>24 hours after pre-hospital dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation assessed by activated partial thromboplastin time (APTT)</measure>
    <time_frame>Immediately upon patient arrival to hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation assessed by activated partial thromboplastin time (APTT)</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation assessed by activated partial thromboplastin time (APTT)</measure>
    <time_frame>24 hours after pre-hospital dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>Immediately upon patient arrival to hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>24 hours after pre-hospital dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular occlusive events (myocardial infarction, stroke, deep venous thrombosis (DVT), pulmonary embolus (PE))</measure>
    <time_frame>Hospital discharge (or up to 28 days in hospital)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of deaths due to bleeding, vascular occlusion (pulmonary embolus, stroke, acute myocardial infarction), multi-organ failure, or head injury</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of deaths due to bleeding, vascular occlusion (pulmonary embolus, stroke, acute myocardial infarction), multi-organ failure, or head injury</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of deaths due to bleeding, vascular occlusion (pulmonary embolus, stroke, acute myocardial infarction), multi-organ failure, or head injury</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of sepsis</measure>
    <time_frame>Hospital discharge (or up to 28 days in hospital)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured using WHODAS 2.0</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured using the EuroQOL 5 dimensions questionnaire (EQ-5D)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious adverse events</measure>
    <time_frame>hospital discharge (or up to 28 days in hospital)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation assessed by fibrinogen</measure>
    <time_frame>Immediately upon patient arrival to hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation assessed by fibrinogen</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation assessed by fibrinogen</measure>
    <time_frame>24 hours after pre-hospital dose of study drug</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood lactate concentration</measure>
    <time_frame>Immediately upon patient arrival to hospital</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of fibrinolytic activity</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of fibrinolytic activity</measure>
    <time_frame>24 hours after first (prehospital) dose of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of plasmin/anti-plasmin complexes</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of plasmin/anti-plasmin complexes</measure>
    <time_frame>24 hours after first (pre-hospital) dose of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of tissue type plasminogen activator (tPA)</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of tissue type plasminogen activator (tPA)</measure>
    <time_frame>24 hours after first (pre-hospital) dose of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of plasminogen activator inhibitor 1 (PAI-1)</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of plasminogen activator inhibitor 1 (PAI-1)</measure>
    <time_frame>24 hours after first (pre-hospital) dose of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of t-PA/PAI-1 complexes</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of t-PA/PAI-1 complexes</measure>
    <time_frame>24 hours after first (pre-hospital) dose of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of thrombin activatable fibrinolysis inhibitor (TAFI)</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of thrombin activatable fibrinolysis inhibitor (TAFI)</measure>
    <time_frame>24 hours after first (pre-hospital) dose of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of interleukins (IL-2, IL-4, IL-6, IL-8, IL-10)</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of interleukins (IL-2, IL-4, IL-6, IL-8, IL-10)</measure>
    <time_frame>24 hours after first (pre-hospital) dose of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of granulocyte macrophage colony-stimulating factor (GM-CSF)</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of granulocyte macrophage colony-stimulating factor (GM-CSF)</measure>
    <time_frame>24 hours after first (pre-hospital) dose of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of interferon gamma</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of interferon gamma</measure>
    <time_frame>24 hours after first (pre-hospital) dose of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of tumour necrosis factor alpha</measure>
    <time_frame>At the end of 8 hour infusion of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory analysis of tumour necrosis factor alpha</measure>
    <time_frame>24 hours after first (pre-hospital) dose of study drug</time_frame>
    <description>Substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>TXA concentration in blood</measure>
    <time_frame>8 hours after first dose of study drug</time_frame>
    <description>substudy</description>
  </other_outcome>
  <other_outcome>
    <measure>TXA concentration in blood</measure>
    <time_frame>24 hours after first dose of study drug</time_frame>
    <description>substudy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1184</enrollment>
  <condition>Wounds and Injuries</condition>
  <condition>Acute Coagulopathy</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As soon as possible after injury, emergency medical services clinicians will administer 1g Tranexamic Acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) delivered intravenously using a slow push of the syringe.
As soon as possible after the patient arrives at hospital, clinicians will administer 1g Tranexamic acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>As soon as possible after injury, emergency medical services clinicians will administer a 10ml ampoule containing 0.9%w/v Sodium Chloride via intravenous injection using a slow push of the syringe (ampoules containing Sodium Chloride appear identical to the ampoules containing Tranexamic Acid).
As soon as possible after the patient arrives at hospital, clinicians will administer a second 10 ml ampoule containing 0.9%w/v Sodium Chloride added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (estimated age 18 years or older)

          -  Injured through any mechanism

          -  Coagulopathy of severe trauma (COAST) score of 3 points or greater

          -  First dose of study drug can be administered within three hours of injury

          -  Patients to be transported to a participating trauma centre

        COAST score

          -  Entrapment (ie in vehicle) [Yes = 1, No = 0]

          -  Systolic blood pressure [&lt;90 mmHg = 2, &lt;100 mmHg = 1, ≥100 mmHg = 0]

          -  Temperature [&lt;32℃ =2, &lt;35℃ = 1, ≥35℃ = 0]

          -  Major chest injury likely to require intervention (e.g. decompression, chest tube)
             [Yes = 1, No = 0]

          -  Likely intra-abdominal or pelvic injury [Yes = 1, No = 0]

        Exclusion Criteria:

          -  Suspected pregnancy

          -  Nursing home residents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell L Gruen, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronica Pitt, PhD</last_name>
    <phone>+613 9903 0343</phone>
    <email>veronica.pitt@monash.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lismore Base Hospital</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Mahoney</last_name>
      <email>Richard.Mahoney@ncahs.health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Maryanne Sewell</last_name>
      <email>Maryanne.Sewell@ncahs.health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>NNSW Medical Retrieval Service</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Mahoney</last_name>
      <email>Richard.Mahoney@ncahs.health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Verdolini</last_name>
      <email>mattverdolini@icloud.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate King</last_name>
      <email>kate.king@hnehealth.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Zsolt Balogh</last_name>
      <email>zsolt.balogh@hnehealth.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CareFlight</name>
      <address>
        <city>Northmead</city>
        <state>New South Wales</state>
        <zip>2152</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Garner</last_name>
      <email>Alan.Garner@careflight.org</email>
    </contact>
    <contact_backup>
      <last_name>Elwyn Poynter</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Orange Base Hospital</name>
      <address>
        <city>Orange</city>
        <state>New South Wales</state>
        <zip>2800</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ambulance Service of New South Wales</name>
      <address>
        <city>Rozelle</city>
        <state>New South Wales</state>
        <zip>2039</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wagga Wagga Base Hospital</name>
      <address>
        <city>Wagga Wagga</city>
        <state>New South Wales</state>
        <zip>2650</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Hsu</last_name>
      <email>Jeremy.Hsu@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Watkins</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St John Ambulance</name>
      <address>
        <city>Darwin</city>
        <state>Northern Territory</state>
        <zip>0810</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Darwin Hospital</name>
      <address>
        <city>Darwin</city>
        <state>Northern Territory</state>
        <zip>0811</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gold Coast Hospital</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Wake</last_name>
      <phone>07 568 74149</phone>
      <email>elizabeth.wake@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Martin Wullschleger, MBBS MD PhD</last_name>
      <email>Martin.Wullschleger@health.qld.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Queensland Ambulance Service</name>
      <address>
        <city>Kedron</city>
        <state>Queensland</state>
        <zip>4031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Australia Ambulance Service</name>
      <address>
        <city>Eastwood</city>
        <state>South Australia</state>
        <zip>5063</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ambulance Tasmania</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ambulance Victoria</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Smith, PhD</last_name>
      <phone>98403752</phone>
      <phone_ext>+613</phone_ext>
      <email>karen.smith@ambulance.vic.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Anthony De Wit</last_name>
      <phone>99459919</phone>
      <phone_ext>+613</phone_ext>
      <email>anthony.dewit@ambulance.vic.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Karen Smith, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony De Wit</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Bernard, MBBS FACEM FCICM FCCM ASM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Bernard, MBBS PhD</last_name>
      <phone>90762000</phone>
      <phone_ext>+613</phone_ext>
      <email>steve.bernard@ambulance.vic.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Biswadev Mitra, MBBS PhD</last_name>
      <phone>90762782</phone>
      <phone_ext>+613</phone_ext>
      <email>biswadev.mitra@monash.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Bernard, MBBS MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Biswadev Mitra, MBBS PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Fitzgerald, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Myles, MBChB MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jamie Cooper, BMBS MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huyen Tran, MBBS(Hons)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dashiell Gantner, BSc MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodney Judson, MBBS</last_name>
      <phone>93427323</phone>
      <phone_ext>+613</phone_ext>
      <email>rodney.judson@mh.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Jonathon Knott, MBBS PhD</last_name>
      <phone>93427543</phone>
      <phone_ext>+613</phone_ext>
      <email>jonathan.knott@mh.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Rodney Judson, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Knott, MBBS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St John Ambulance Western Australia</name>
      <address>
        <city>Geraldton</city>
        <state>Western Australia</state>
        <zip>6530</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St John Ambulance</name>
      <address>
        <city>Albany</city>
        <zip>0632</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Smith</last_name>
      <email>tony.smith@stjohn.org.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin McArthur</last_name>
      <email>colinm@adhb.govt.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton West</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grant Christey</last_name>
      <email>grant.christey@waikatodhb.health.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wellington Free Ambulance</name>
      <address>
        <city>Wellington</city>
        <zip>6011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andy Swain</last_name>
      <email>andy.swain@wfa.org.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Young</last_name>
      <email>Paul.Young@ccdhb.org.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <reference>
    <citation>Gruen RL, Jacobs IG, Reade MC; PATCH-Trauma study. Trauma and tranexamic acid. Med J Aust. 2013 Sep 2;199(5):310-1.</citation>
    <PMID>23992173</PMID>
  </reference>
  <reference>
    <citation>Reade MC, Pitt V, Gruen RL. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock. 2013 Aug;40(2):160-1. doi: 10.1097/SHK.0b013e31829ab240.</citation>
    <PMID>23860584</PMID>
  </reference>
  <reference>
    <citation>Mitra B, Mazur S, Cameron PA, Bernard S, Burns B, Smith A, Rashford S, Fitzgerald M, Smith K, Gruen RL; PATCH-Trauma Study Investigators. Tranexamic acid for trauma: filling the 'GAP' in evidence. Emerg Med Australas. 2014 Apr;26(2):194-7. doi: 10.1111/1742-6723.12172.</citation>
    <PMID>24708011</PMID>
  </reference>
  <reference>
    <citation>Gruen RL, Mitra B. Tranexamic acid for trauma. Lancet. 2011 Mar 26;377(9771):1052-4. doi: 10.1016/S0140-6736(11)60396-6.</citation>
    <PMID>21439636</PMID>
  </reference>
  <reference>
    <citation>Mitra B, Cameron PA, Mori A, Maini A, Fitzgerald M, Paul E, Street A. Early prediction of acute traumatic coagulopathy. Resuscitation. 2011 Sep;82(9):1208-13. doi: 10.1016/j.resuscitation.2011.04.007. Epub 2011 Apr 21.</citation>
    <PMID>21600687</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2014</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Monash University</investigator_affiliation>
    <investigator_full_name>Russell Gruen</investigator_full_name>
    <investigator_title>Professor of Surgery and Public Health</investigator_title>
  </responsible_party>
  <keyword>Wounds and Injuries</keyword>
  <keyword>Acute Coagulopathy</keyword>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Emergency Medical Services</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

